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Objective. To assess the relationship between closer monitoring of depressed patients
during high-risk treatment periods and death from suicide, using two analytic approaches.
Data Source. VA patients receiving depression treatment between 1999 and 2004.
Study Design. First, a case–control design was used, adjusting for age, gender, and
high-risk days (1,032 cases and 2,058 controls). Second, an instrumental variable (IV)
approach (N 5 714,106) was used, with IVs of (1) average monitoring rates in the VA
facility of most use and (2) monitoring rates of VA facilities weighted inversely by
distance from patients’ residences.
Principal Findings. The case–control approach indicated a modest increase in sui-
cide risk with each additional visit (odds ratio 5 1.02; 95 percent confidence inter-
val 5 1.002, 1.04). The ‘‘facility used’’ IV estimate indicated near zero change in risk
(0.0008 percent increase; p 5 .97) with each additional visit, while the distance-weighted
IV estimate indicated a 0.032 percent decrease in risk (p 5 .29). An alternative analysis
assuming a threshold effect of  4 visits during high-risk periods also showed a
decrease (0.15 percent; p 5 .08) using the distance IV.
Conclusions. The IV approach appeared to address the selection bias more appro-
priately than the case–control analysis. Neither analysis clearly indicated that closer
monitoring during high-risk periods was significantly associated with reduced suicide
risks, but the distance-weighted IV estimate suggested a potentially protective effect.
Key Words. Suicide, HEDIS visit, depression treatment, case–control, instrumental
variable
Suicide is the 11th leading cause of death in the United States (National Center
for Injury Prevention and Control, Center for Disease Control [CDC]). To




reduce suicide-related mortality, the Institute of Medicine (2004) has called for
improvements in suicide surveillance, monitoring, and prevention. Close
clinical monitoring of individuals during high-risk periods is often suggested as
one way to reduce suicide deaths, and the U.S. Food and Drug Agency (FDA)
has recommended closer monitoring for children, adolescents, and young
adults starting antidepressants or changing doses to reduce suicide risks at
these times. The most stringent FDA recommendation for monitoring sug-
gested that seven clinical visits be completed in the 12 weeks following these
antidepressant treatment events (U.S. Food and Drug Administration). Close
clinical monitoring has also been suggested for patients (of any age) who are
recently discharged from psychiatric inpatient stays, another high-risk period
for suicide (American Psychiatric Association 2003).
However, intensive monitoring following antidepressant changes does
not appear to be the norm. Only 23 percent of patients enrolled in a large
managed care organization and 6 percent of patients in the Veterans Health
Administration (VHA) system who started new antidepressant treatment re-
ceived seven or more visits in the first 12 weeks following these antidepressant
starts (Stettin et al. 2006; Valenstein et al. 2009). Providing more intensive
monitoring during these treatment periods would require substantial reorga-
nization of mental health services. Health systems likely will require solid
evidence for the effectiveness of close monitoring in reducing suicide before
making these substantial service changes.
To date, no published studies have systematically evaluated the impact
of intensive clinical monitoring on suicide deaths. Demonstrating such a link is
difficult due to the low base rate of completed suicide and the resulting need
for extremely large sample sizes (Gunnell, Saperia, and Ashby 2005; Simon
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et al. 2006). Sample sizes required to examine meaningful differences in sui-
cide rates with alternative treatment interventions are estimated at 300,000 or
more——numbers that preclude using randomized-controlled trials for this
purpose (Gunnell, Saperia, and Ashby 2005; Simon et al. 2006). Administra-
tive data from large health care organizations can provide the necessary sam-
ple size, but they raise an important methodological issue of confounding by
treatment indication. In clinical settings, treatment receipt is influenced by a
mixture of patient, provider, and organizational factors. If more severely ill
patients are channeled to a particular treatment (e.g., increased monitoring)
and are more likely to have adverse outcomes, this may result in spurious
associations between increased monitoring and suicide (Prentice et al. 2005).
A bias in the opposite direction may also arise if providers and organizations
with more intensive monitoring provide higher quality care in other unmea-
sured dimensions.
In this study, we used data from a large national cohort of VHA patients
in depression treatment to investigate the relationship between more intensive
monitoring during high-risk treatment periods and suicide. Recognizing the
potential for bias, we used two different analytic approaches to address con-
founding by treatment indication. We first used a case–control design, ad-
justing for all known characteristics available in the administrative databases
that might be associated with both increased monitoring and suicide. The
traditional case–control design allows matching of cases with controls in order
to assess the relationship between the primary exposure variable and outcome
of interest while controlling for the matching variables as well as the undefined
variables associated with the matching variables. We subsequently used an
instrumental variable (IV) approach to address potential biases due to vari-
ables not available in the administrative databases (Newhouse and McClellan
1998; Fortney et al. 2001; Salkever et al. 2004).
These two approaches each have potential advantages and disadvan-
tages. The case–control approach is well suited for studying uncommon events
and is intuitively straightforward. However, it is limited by the patient and
facility characteristics available in the administrative or study databases,
and it can produce biased results when factors unavailable in these databases
influence both the level of monitoring and the likelihood of suicide. In theory,
the IV approach can account for unmeasured confounders, but its validity
depends on the appropriateness of the chosen IV. This approach typically
involves a loss of statistical power, because it is based on variation in treatment
due to specific factors (the IVs) rather than the full variation in treatment.
The loss in statistical power may particularly limit the application of the IV
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approach where the event of interest has a low base rate. We compared these
two methods, with the ultimate goal of assessing whether increased monitoring
during high-risk treatment periods reduces suicide deaths.
METHODS
Study Sample
Study data were drawn from a cohort of 887,859 patients receiving depression
treatment between April 1, 1999 and September 30, 2004 in the VHA health
system, but the size and composition of the samples differed slightly for the
two approaches. Patients were included in the overall depression treatment
cohort if they received both a diagnosis of a depressive disorder and an an-
tidepressant medication fill from VHA providers, or if they had two encoun-
ters with diagnoses of depressive disorders. Patients were excluded if they
received any diagnosis of bipolar I, schizophrenia, or schizoaffective disorder
during the study period. Several prior studies and accrediting agencies have
used similar definitions to define cohorts with depressive disorders when ex-
amining the quality of care for depression (Kerr et al. 2000; Charbonneau et al.
2003; Spettell et al. 2003; National Committee on Quality Assurance 2006).
Because patients who died soon after entering the cohort had limited obser-
vation time, making monitoring rates difficult to calculate and important pa-
tient characteristics difficult to assess, patients with o84 observation days
were excluded from the primary study analyses (although they were included
in sensitivity analyses), resulting in a cohort of 835,944 patients.
Study Measures
Suicide. National Death Index (NDI) Plus includes national data regarding
dates and causes of death for all U.S. residents, derived from death certificates
filed in state vital statistics offices. As outlined in a prior report based on the
same treatment cohort (Zivin et al. 2007), NDI queries were submitted for
cohort patients with a date of death in the VA Beneficiary Identification and
Records Locator System Death File during the study period and for patients
who did not use VHA services in the year following the study period,
resulting in a comprehensive assessment of all suicide deaths in the study
population.
High-Risk Periods and Intensity of Clinical Monitoring. High-risk periods
for suicide were defined as the 12-week (84 day) periods immediately
following psychiatric hospitalizations, new antidepressant (AD) starts, other
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antidepressant starts, or antidepressant dose changes ( 50 percent change in
dose between two consecutive fills of a specified AD occurring within 6
months) (Valenstein et al. 2007). Monitoring visits were defined using Health
and Employment Data and Information Set (HEDIS) criteria modified for the
VHA setting (National Committee on Quality Assurance 2006). A HEDIS
monitoring visit is an outpatient visit that has a psychiatric current proce-
dural terminology (CPT) code or a nonpsychiatric CPT code accompanied
by a mental health diagnosis. On any given high-risk day, only one
monitoring visit was counted, even if more than one qualifying visit occurred.
The intensity of monitoring was calculated as the HEDIS visit rate during the
high-risk periods. Inpatient days were excluded from these high-risk periods,
as we were interested in the relationship between outpatient monitoring and
suicide deaths.
Covariates. Patient covariates included age categories, race, Hispanic
ethnicity, sex, diagnoses of substance use disorder, posttraumatic stress
disorder (PTSD), major depression, personality disorder, anxiety disorder
and bipolar II, service connection (indicating disability from conditions
newly occurring or exacerbated by military service), Charlson medical
comorbidity index, use of services with Medicare claims, E-code indicating a
suicide attempt, VA psychiatric hospitalization, psychiatric inpatient days,
number of psychotropic medications, and number of years since cohort
entry. The choice of these covariates was based on the prior literature
regarding suicide risk factors and patient factors associated with increased
monitoring levels, including our teams’ prior paper on risk factors for suicide
within this VA population (Simon 1992; Zivin et al. 2007). Facility-level
variables included geographic region of the facility of most use in the year and
an indicator of whether the facility was in an urban area. Psychiatric
comorbidities were defined based on data from 6 months before cohort entry
through the end of the study period. Covariates other than psychiatric
comorbidities were defined based on data from the 12 months before cohort
entry.
Study Analyses
Case–Control Design and Analyses
Matching. For each suicide case, we matched one to two control patients
based on demographics and risk factors for suicide. The matching variables
were chosen so that cases and controls were at risk in the same time period
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with a similar duration of depression treatment and potentially similar illness
severity. Control patients were matched individually to a case, randomly
chosen with replacement from a pool of control patients who were alive on
the date when the case died of suicide (index date), with similar numbers of
total observation days (  60 days) as the case before this index date, within
 5 years of the case birth year, of the same sex, and with similar numbers of
high-risk days within 12 months before the index date (  30 high-risk days).
When more than two possible controls satisfied the matching criteria, we
randomly selected two controls. A total of 1,537 suicide cases were identified;
5 cases without a matching control were excluded. We then limited the case–
control analyses to the 3,090 patients (1,032 cases and 2,058 controls) with at
least one high-risk day in the year before their index date.
Statistical Analyses. Conditional logistic regression models were used to
evaluate the relationship between suicide and intensity of monitoring during
high-risk days. The primary predictor was the HEDIS visit rate calculated for
the high-risk days in the year before the index date. Logistic models included
the covariates listed above. The analysis was also conducted using a gener-
alized linear model with case as the response variable with logit link, matched
sets as the clusters, and HEDIS visit rate as the primary predictor. A Cox
proportional hazard model was also used to assess time from cohort entry
until suicide or the index date, with late entry at 1 year before index date for
patients having 41 year of observation. In these analyses, we categorized the
HEDIS visit rate into five dummy variables to check for a nonlinear rela-
tionship, and we stratified by index year to assess whether the effect of mon-
itoring changed across study years.
Sensitivity Analyses. All analyses were repeated using the subset of cases
(and their matching controls) who survived at least a year after their depres-
sion diagnosis. We also completed analyses using a newly pulled case–control
dataset without the restriction of patients having at least 84 observation days
after cohort entry.
IV Design and Analysis
Analytic Dataset. All patients in the depression cohort from fiscal year
(FY) 2000 to 2004 with at least 84 observation days and one high-risk day
were included (N 5 706,280). FY 1999 data were excluded because the data
were available only for part of the year. The analytic dataset included
1,295,321 yearly patient-level observations, including HEDIS monitoring
rates defined for each year. For the primary IV analysis, we excluded yearly
1210 HSR: Health Services Research 45:5, Part I (October 2010)
data with o14 high-risk days because HEDIS monitoring rates may not be
reliable when patients have small numbers of high-risk days. As the research
question pertains to policies regarding minimal levels of monitoring, the pri-
mary analytic dataset also excluded yearly data from those with HEDIS visit
rates 47 visits per 84 high-risk days, although this was subjected to sensitivity
analysis. This gave 1,168,589 observation years from 682,001 unique patients
for the primary IV analysis.
IV Model. We used two-stage IV regression model. The first stage was
Rit ¼ aot þ a1t Vit þ a2Xit þ eit
where Rit is the monitoring level of patient i at year t (endogenous variable),
Vit is the IV, and eit is the effect of the unmeasured factors that affect mon-
itoring rate. Xit includes variables known to affect suicide risks and potentially
associated with increased monitoring (Zivin et al. 2007) (listed earlier under
‘‘Covariates’’) and dummy variables for each FY. In the second stage,
we estimated the yearly completed suicide linear regression model using
the predicted monitoring rate from the first-stage model for each patient, R̂it ,
and the Xit.
An IV approach requires identifying IVs that predict levels of clinical
monitoring but are not correlated with suicide, conditional on the level of
monitoring (Newhouse and McClellan 1998). We constructed two alternative
IVs, both based on the idea that practice patterns of VA facilities closest to
one’s residence may affect the type of treatment that one receives but may not
be related to unmeasured factors that affect health outcomes. The first IV
represented the average intensity of depression monitoring during high-risk
periods for all patients at the facility used most often by the individual. For
each individual, this IV was calculated as the average number of outpatient
depression monitoring visits provided to all depressed VA patients (exclud-
ing the individual himself) during high-risk periods in the facility where the
individual received the majority of his/her outpatient care during each FY.
The second IV was a distance inverse-weighted average of the mon-
itoring rates of all VA facilities based on the facility’s distance from each







where Mk was the average monitoring level of kth facility, the weights (wk)
were the inverse of the square root of distance to each facility from the cen-
troid of each individual’s zip code, and n was the number of facilities in the
Examining the Relationship between Clinical Monitoring and Suicide Risk 1211
VA. IV approaches based on distance to facilities have been used in the
health services research literature starting with McClellan, McNeil, and
Newhouse (1994).
We used these two different IVs because we hypothesized that each
would offer distinct advantages. We expected that the first IV would be more
strongly predictive of the monitoring intensity that a patient receives (the first
condition of a valid IV), because this IV is a function of practice patterns only
at the facility that the patient attends most. On the other hand, we expected
that the second IV would be less likely to be correlated with unmeasured
factors that affect health outcomes (the second condition of a valid IV),
because it is a distance-weighted practice patterns of surrounding facilities,
determined solely by where one lives rather than the facility one attends the
most (which may be affected by unmeasured severity level).
Statistical Analyses. To produce unbiased and consistent estimates, the
IV should be (1) associated with the patient-level monitoring and (2) not
associated with unmeasured patient or facility characteristics that are likely to
affect suicide. To assess the first property for each of the two IVs, we checked
the first-stage relationship between patient-level monitoring rate, Rit, and
each IV using linear regression, controlling for Xit. To assess the second
property, we compared the distribution of individual and facility-level char-
acteristics between individuals with lower versus higher values than the me-
dian IV value, and across the individuals of quartiles based on IV values.
Finding groups to be similar for most measured characteristics would
strengthen the case that the IV was not related to unmeasured differences. Our
distance-weighted IV estimate might also be confounded if people move
closer to facilities that practice more intensive (or less intensive) monitoring
because of unmeasured severity of their condition. To explore this further, we
looked at a subset of people who moved their residence (on a yearly basis) to
see if those who move closer to facilities that practice more versus less in-
tensive monitoring are different in their severity. Finally, we used a two-stage
regression based on a linear probability model to examine the relationship
between suicide and the IV, adjusting for the covariates Xit. The model was
estimated using a two-stage model with robust standard errors to account for
potential heterogeneity of the error terms within multiple years of data from a
person. We used the Hausman test to assess whether there was a significant
difference between the parameter estimates of the IV and the naı̈ve analysis
estimate using monitoring rate as the predictor (Hausman 1978).
Sensitivity Analyses. To confirm that results did not vary by year, we fit
the model separately by each FY and assessed whether the direction of the
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relationship remained consistent across years. IV estimates were also ob-
tained using two-stage least random-effect estimators to account for multiple
years of data from each person. Because excluding data with HEDIS visit
rates 47 per 84 high-risk days may bias the sample toward less severe cases
for suicide risk, sensitivity analyses was done including data with HEDIS visit
rates 47. Because treatment from non-VA providers is less common for
those with the service connection, we also did subgroup analysis of the per-
sons with a service connection to see whether the results are more reliable in
this subgroup. Lastly, recognizing that an increase in monitoring may affect
suicide only if it reaches a certain intensity, we conducted an analysis where a
threshold monitoring effect was assumed at  4 visits, as the average in-
crease to bring patients to 7 visits during high-risk periods was 3.5 visits.
RESULTS
Table 1 shows the mean HEDIS monitoring rate for the entire depression
cohort with  84 observation days in the first 12 months following cohort entry
(N 5 835,944) and for the subsets of patients who had  1 or  14 high-risk
days in the first 12 months following entry. Monitoring rates were higher among
patients with indications of more severe psychiatric illness, such as having psy-
chiatric hospitalizations or diagnoses of substance use disorder or posttraumatic
stress disorder (PTSD). These characteristics are also associated with increased
rates of suicide in this population, (Zivin et al. 2007) suggesting that confounding
of the relationship between monitoring and completed suicide by treatment
indication is plausible and may be an important source of bias.
Case–Control Analysis
For matched cases and controls, the monitoring rates during high-risk periods
were similar. Cases had a mean HEDIS visit rate of 2.9 visits (SD 5 5.3) per 84
high-risk days, while controls had 2.7 visits (SD 5 5.0). Table 2 shows demo-
graphics and other patient characteristics for cases and controls. Despite
matching on index date, sex, age, gender, period of observation, and numbers
of high-risk days, cases were still more likely than controls to be white, non-
Hispanic, to receive larger numbers of psychotropic medications, and less
likely to have comorbid PTSD or a service connection. Unadjusted odds ratio
(OR) of suicide associated with an increase of one HEDIS visit per 84 high-risk
day period was 1.00 (p 5 .27), and covariate adjusted OR was 1.02 (p 5 .03,
Table 3).
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Table 2: Case–Control Analysis——Demographic Characteristics and Other
Variables by Suicide for Patients and Controls Who Had At Least One










Male 2,983 (96.5) 996 (96.5) 1,987 (96.6) .9561
Age (Mean [SD]) 56.0 (13.4) 55.9 (13.6) 56.0 (13.2) .8657
Race
White 2,448 (79.2) 860 (83.3) 1,588 (77.2) o.0001
Black 368 (11.9) 42 (4.1) 326 (15.8)
Other 49 (1.6) 19 (1.8) 30 (1.5)
Unknown 225 (7.3) 111 (10.8) 114 (5.5)
Hispanic 142 (4.6) 30 (2.9) 112 (5.4) .0018
Substance abuse 1,214 (39.3) 413 (40.0) 801 (38.9) .5556
Bipolar II diagnosis 76 (2.5) 29 (2.8) 47 (2.3) .3739
Other anxiety diagnosis 1,114 (36.1) 381 (36.9) 733 (35.6) .4773
Personality disorder 355 (11.5) 120 (11.6) 235 (11.4) .8635
PTSD 951 (30.8) 262 (25.4) 689 (33.5) o.0001
Service connected 1,042 (33.7) 301 (29.2) 741 (36.0) .0002
Charlson score
0 1,633 (52.9) 572 (55.4) 1,061 (51.6) .1342
1 648 (21.0) 205 (19.9) 443 (21.5)
2 261 (8.5) 83 (8.0) 178 (8.7)
3 297 (9.6) 97 (9.4) 200 (9.7)
43 251 (8.1) 75 (7.3) 176 (8.6)
Had a psychiatric stay 702 (22.7) 232 (22.5) 470 (22.8) .8232
Number of comorbid psychiatric diagnoses
0 930 (30.1) 312 (30.2) 618 (30.0) .2184
1 1,062 (34.4) 370 (35.9) 692 (33.6)
41 1,098 (35.5) 350 (33.9) 748 (36.4)
Number of psychiatric medications
0 291 (9.4) 85 (8.2) 206 (10.0) .0003
1 1,165 (37.7) 362 (35.1) 803 (39.0)
2 755 (24.4) 260 (25.2) 495 (24.1)
3 447 (14.5) 153 (14.8) 294 (14.3)
43 432 (14.0) 172 (16.7) 260 (12.6)
Medicare use 831 (26.9) 291 (28.2) 540 (26.2) .2469
Suicide attempt 42 (1.4) 16 (1.6) 26 (1.3) .5165
Major depression 1,017 (32.9) 352 (34.1) 665 (32.3) .3165
Region northeast 544 (17.7) 175 (17.1) 369 (18.0) .8970
Central 680 (22.1) 228 (22.2) 452 (22.0)
South 1,190 (38.6) 395 (38.5) 795 (38.7)
West 666 (21.6) 228 (22.2) 438 (21.3)
Urban 2,775 (90.1) 905 (88.2) 1,870 (91.0) .0133
nComparing cases to controls.
PTSD, posttraumatic stress disorder.
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In sensitivity analyses, the positive relationship between monitoring and
suicide persisted (OR 5 1.03, p 5 .05) even when the analysis was limited to
1,547 patients (525 cases and 1,022 controls) who lived more than a year
following their cohort entry. Similar results were obtained when the HEDIS
visit rate was entered as five dummy categorical variables to check for non-
linear relationships. The GENMOD model with logit link also resulted in an
adjusted OR of 1.02 (p 5 .01) when all cases were included and an adjusted
OR of 1.03 (p 5 .03) when the analysis was limited to those who lived more
than a year following cohort entry. A Cox proportional hazard model with late
entry did not give different results. The OR was also very similar when cases
(and their matching controls) with HEDIS visit rate 47 were excluded
(OR 5 1.07, confidence interval [CI] 5 1.01, 1.13) and when using newly
pulled case–control dataset that did not exclude those with o84 observation
days (OR 5 1.02, CI 5 1.01, 1.03).
IV Analysis
Table 4 shows patient-level monitoring is significantly higher for patients
in high-intensity monitoring facilities (higher than median) than in low-
intensity monitoring facilities, supporting the first criterion for a valid IV.
Similarly, when patients were grouped into smaller increments of facility-level
Table 3: Case-Control Analysis——From Conditional Logistic Regression
Model for the Relationship between Suicide and HEDIS Visit Rate
Variable Adjustedn Odds Ratios 95% CI p-Value
HEDIS visit rate 1.02 (1.002, 1.04) .0253
Blackw 0.24 (0.17, 0.34) o.0001
Other racew 1.23 (0.67, 2.25) .5101
Unknown racew 1.91 (1.40, 2.59) o.0001
Hispanic 0.54 (0.35, 0.82) .0041
PTSD 0.58 (0.44, 0.78) .0003
Number of psychiatric medications 1.18 (1.11, 1.25) o.0001
Service connection 0.79 (0.65, 0.95) .0132
Number of psychiatric stays 0.86 (0.73, 0.998) .0475
Number of days since depression diagnosis 0.996 (0.993, 0.999) .0200
nIn addition to the listed variables, the model is adjusted also for Charlson scores (0, 1, 2, 3, or43),
any substance abuse, bipolar II diagnosis, personality disorder, anxiety disorder, major depres-
sion, Medicare use, number of psychiatric disorder diagnoses (0, 1, or 41), number of psychiatric
stay days, suicide attempts (E-code), and region and urban status of facility of most use in the year
before study entry. None of these variables had a p-value o.05.
wReference group is white race.
HEDIS, Health and Employment Data and Information Set; PTSD, posttraumatic stress disorder.
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Table 4: Instrumental Variable Analysis——Patient Characteristics by High
Versus Low Facility-Level Monitoring (IV; Dichotomized at the Median Rate
of 2.22 Visits per 84 High-Risk Days) and by High Versus Low Distance
Inverse-Weighted Facility-Level Monitoring (Distance IV; Dichotomized at
the Median of 2.31) Based on Patient Years Data from Fiscal Years 2000 to
2004 with at Least 14 High-Risk Days in Each Year
Facility Monitoring
IV Distance IV
Low High Low High
Number of observation 632,728 599,548 637,268 595,008
Yearly suicide probabilityn 53.0 56.1 53.7 56.3
Endogenous
HEDIS visit ratew 1.74§§ 2.56 1.85§§ 2.45
Age 57.4§§ 56.8 57.0§§ 57.2
Male (%) 91.5§§ 91.3 91.2§§ 91.7
White (%) 79.6§§ 75.7 77.2§§ 78.2
PTSD (%) 25.9§§ 31.2 26.8§§ 30.3
Bipolar II (%) 1.2§§ 1.8 1.2§§ 1.9
Personality disorder (%) 5.0§§ 6.2 4.8§§ 6.3
Major depression (%) 26.3§§ 32.8 28.6§§ 30.4
Anxiety disorder (%) 32.5 32.5 31.3§§ 33.8
Substance use (%) 23.9§§ 30.6 24.7§§ 29.8
Suicide attempt (%) 0.65§ 0.60 0.72§§ 0.52
Psychiatric daysz 2.51§§ 4.15 2.67§§ 3.99
Psychiatric staysz 0.13§§ 0.17 0.13§§ 0.17
Medicationsz 1.86§§ 1.80 1.90§§ 1.76
Medicare use (%) 31.5§§ 26.3 29.9§§ 28.0
Charlson score  1 (%) 52.8§§ 50.9 53.7§§ 50.0
Service connected (%) 33.2§§ 33.7 33.1§§ 33.8
Region (%)
Northeast 15.5§§ 22.7 11.0§§ 27.6
Central 19.1 24.9 23.3 20.5
South 56.1 20.5 54.4 22.0
West 9.4 31.9 11.4 29.9
Facility in urban area (%) 86.1§§ 94.0 89.1§§ 90.9
Facility bed size 644§§ 533 641§§ 535
Fiscal year (%)
2000 6.0§§ 15.8 0.07§§ 21.6
2001 12.8 18.5 0.39 30.8
2002 22.6 17.9 20.0 20.4
2003 29.5 18.7 42.2 6.0
2004 28.9 22.3 37.3 13.9
Note. Values are means unless specified as %.
nPer 100,000 persons.
wHEDIS monitoring visit rate expressed as per 84 high-risk days.
zPsychiatric days are inpatient psychiatric hospitalization days in the previous year, and psychi-
atric stays are the number of inpatient psychiatric hospitalizations in the previous year.
§p-value is o.05.
zNumber of psychotropic medications prescribed in the previous year.
§§p-value is o.001 for comparison between patients with low versus high facility-level monitoring.
HEDIS, Health and Employment Data and Information Set; PTSD, posttraumatic stress disorder.
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monitoring, the mean patient-level HEDIS monitoring rates increased from
1.3 in patients with the lowest facility-level monitoring (between 1.1 and 1.3) to
2.4 in those with the highest facility monitoring level (between 5.7 and 5.9). In
addition, the Kleibergen–Paap test of underidentification (Kleibergen and
Paap 2006) testing for the correlation between the IVs and the patient-level
monitoring was significant (po.001) for both our IVs.
The second property for a valid IV cannot be tested directly, but ex-
amining how measured covariates correlate with the IV can give a sense of
whether unmeasured differences are likely to be associated with suicide and
thus consequential. Patient and facility characteristics in Table 4 for low-
versus high-monitoring facilities based on each IV show similarity of several
patient-level characteristics between these categories, particularly the nearly
identical distributions of gender, age, anxiety, and comorbidity status. How-
ever, substantial differences between low- versus high-monitoring facilities
are seen in the numbers of psychiatric inpatient days, psychiatric and sub-
stance use diagnoses, and geographic region, which may reflect idiosyncratic
differences in diagnosis and practice patterns across geographic areas. We
note that although these differences are substantial in some cases, they are
much smaller than the differences between high versus low patient-level mon-
itoring groups (not shown), suggesting that the IV estimate may be less prone
to treatment indication bias than a standard single equation approach. We also
did not find any patterns in severity such as more inpatient psychiatric days or
higher percent of psychiatric illnesses in patients who moved closer to facilities
practicing more intensive monitoring than those who moved closer to facilities
practicing less intensive monitoring. Lastly, as an indirect test of the second
property, we tested for the relationship between suicide and the IVs, condi-
tional on the patient level of monitoring and other covariates and found that it
was not significant (p 5 .91 for the IV and .24 for distance-weighted IV).
The first-stage model (Appendix SA2), with the endogenous patient-
level monitoring as the dependent variable, indicated that 13.0 percent of
variation in monitoring rate is explained by the average facility-level mon-
itoring and other exogenous variables. Similarly, 12.5 percent of the variation
in patient-level monitoring is explained by the distance inverse-weighted av-
erage facility-level monitoring and other exogenous variables. In particular,
each additional facility-level average visit and distance inverse-weighted fa-
cility-level visit was associated with an unadjusted estimate of 0.28 (po.001)
and 0.70 (po.001) more patient visits during high-risk periods, respectively.
After adjusting for other patient and facility characteristics variables, the es-
timates were 0.20 (partial F-test, po.001) for facility-level average monitoring
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and 0.99 (partial F-test, po.001) for distance inverse-weighted facility-level
monitoring. Both IVs were strong predictors of patient-level monitoring;
however, the IV based on average monitoring at the facility of most use had a
standard deviation 3.5 times larger than that of the IV based on distance-
weighted monitoring practices, indicating that it provides more variation and
therefore more statistical power (though at the possible expense of higher bias,
as noted earlier). Other patient characteristics, such as psychiatric hospital-
ization and comorbid psychiatric conditions, showed the expected positive
relationships with monitoring.
An unadjusted ‘‘naı̈ve’’ linear probability model estimate showed that
suicide increased by 0.003 percent (p 5 .03) with each additional monitoring
visit. After adjusting for the full set of patient and facility covariates, suicide still
increased by 0.003 percent (p 5 .05) with each additional monitoring visit.
The IV estimate (Table 5) using facility-level monitoring indicated a positive
and insignificant association (0.0008 percent, p 5 .97) in suicide with each
Table 5: Instrumental Variable (IV) Analyses——The Estimates Are of
HEDIS Monitoring Rate from IV Analysis with Facility-Level Monitoring
as an IV and with Distance Inverse-Weighted Facility Monitoring as an IV,
Based on Linear Probability Model of Suicide
IV Estimate Distance IV Estimate
Estimate (SE) p-Value Estimate (SE) p-Value




0.000075 (0.000217) .731  0.000165 (0.000526) .753
Data includes HEDIS
rate 47
 0.000014 (0.000056) .797  0.000120 (0.000068) .080
Service connected
patients only
 0.000392 (0.000308) .203  0.000688 (0.000401) .087
Note. All models were adjusted for age categories, male, race, Charlson comorbidity score (0, 1, 2,
3), psychiatric stays in prior year, psychiatric hospitalization days in prior year, number of
psychotropic medication in prior year, posttraumatic stress disorder, service connection, sub-
stance abuse, bipolar II, personality disorder, major depression, anxiety, suicide attempt in prior 3
years, urban facility, geographical region of facility of most use in each year, and number of years
since depression diagnosis.
Primary analysis used patient-year data in the national cohort of VA patients in depression treat-
ment from fiscal years 2000–2004, included data when number of high-risk days was at least 14 in
the year, and excluded data with HEDIS monitoring rate 47.
HEDIS, Health and Employment Data and Information Set.
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additional monitoring visit. On the other hand, the distance-weighted IV es-
timate indicated a decrease in suicide of 0.032 percent with each additional
visit, although still not statistically significant (p 5 .29). Hausman tests failed to
reject that there is no endogeneity, indicating that the difference in coefficients
between the naı̈ve and IV analysis was not significant using either IV.
When a random-effects model was used instead of robust standard er-
rors, we found the estimates to differ in size, but there was no change in these
basic patterns. IV estimates from models fit separately by each year varied by
year with both IVs, but with no consistent direction of association——that is, the
estimates neither increased nor decreased in years. IV estimates based on data
that included patients with HEDIS rates 47 and estimates based on data that
included only patients with a service connection both estimated a decrease in
suicide risk with increased monitoring using either IV. Thus, all estimates,
although not statistically significant, suggested a reduction in suicide (Table 5).
Lastly, a model with a threshold effect of  4 visits during high-risk periods
showed a decrease of 0.011 percent (p 5 .88) in suicide risks using facility
monitoring IV and a decrease of 0.151 percent (p 5 .08) using the distance-
based IV.
CONCLUSION
We used data from a large national cohort of VHA patients receiving de-
pression treatment to complete the first comprehensive assessment of mon-
itoring visits and suicide deaths. We show that in this observational dataset,
patient-level characteristics associated with higher risks of suicide (Spettell
et al. 2003) were also associated with higher levels of monitoring, suggesting
there are likely substantial treatment selection biases when assessing the
relationship between suicide and clinical monitoring.
We used two analytic approaches to examine the link between mon-
itoring and suicide while addressing these treatment selection biases, the tra-
ditional case–control approach and an IV approach——and we found that these
analytic approaches resulted in different conclusions.
Although widely used, traditional case–control analyses with the cov-
ariate data available in large administrative databases appeared unsuccessful
in addressing treatment selection biases. Case–control analyses indicated that
visits with clinicians were significantly associated with a slight increase in sui-
cide deaths among patients during high-risk periods. This would seem an
unlikely scenario unless one believes that clinical contacts increase patient
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distress or impulsivity. Instead, this finding is likely due to residual treatment
indication biases because of insufficient patient information in administrative
data to adjust for factors associated with both monitoring and suicide.
Although some IV analyses based on facility of most use suggested no
impact of monitoring on suicide risk, several IV analyses, particularly those
using the distance-weighted IV, produced results more in line with expert
opinion, suggesting that increased monitoring may lead to reduced suicide
risks. However, none of the IV results were statistically significant.
IV estimates may be less subject to treatment indication biases than
either the naı̈ve single equation estimate or the case–control study estimates,
and they may more closely address policy questions of whether to increase or
decrease monitoring for defined populations during high-risk periods. IV an-
alyses assess the marginal impact of increases in monitoring visits——the impact
of increased monitoring for individuals who receive this closer monitoring
only because of differences in facility practices (Newhouse and McClellan
1998). Some patients, because of high-risk behaviors, will receive high levels of
monitoring regardless of usual facility practices, and IV estimates do not re-
flect the benefit these individuals receive from close monitoring. However,
because IV approaches focus only on treatment variation that can be ex-
plained by the IV, these analyses tend to produce larger standard errors than
more direct methods. Likely due to this imprecision and low base rate of
completed suicide, IV analyses did not provide a definitive answer regarding
the relationship between closer monitoring and suicide despite the use of a
large administrative database (Sturm 1998).
We note that while insignificant findings in IV analyses might be due to
residual bias or imprecision, it is also possible that clinical visits as currently
practiced are not effective in reducing suicide (though they may be effective in
addressing other concerns). Routine clinical visits may fail to include a careful
assessment of suicidal ideation, plans, or access to lethal means. Alternatively,
suicidal ideation or other clinical indicators of risk may not be present during
routinely scheduled visits. Suicide attempts are often impulsive and are fre-
quently planned for o30 minutes before being enacted (Simon et al. 2001).
Therefore, even large increases in monitoring (e.g., more than four contacts)
over the course of 84 days may not be sufficient to detect these short periods of
acute risk. Finally to date, even if acute suicide risk is detected during a visit,
few clinical interventions have been shown to be effective in reducing these
risks (Mann et al. 2005). These possibilities, in combination with our lack of a
robust finding for a protective effect, highlight a need to further refine and
evaluate additional clinical approaches for reducing suicide risks.
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We have reported previously that increasing monitoring from current
levels to FDA suggested levels would mean a substantial reorganization of
health services along with substantial incremental costs (Valenstein et al.
2009). As noted previously, RCTs of sufficient size to demonstrate a clear link
between monitoring and suicide deaths are impractical, and we now show that
using observational data (in which clinicians are following individuals they
deem at greater risk more closely) to demonstrate a clear link between higher
levels of monitoring and reduced suicide mortality is also difficult——even
when using case–control and IV analyses to address treatment biases. Given
the difficulty in demonstrating this link, we believe health care organizations
and clinicians will remain unwilling to change current behaviors and press
forward with implementing broad policy recommendations regarding mon-
itoring——unless a public consensus develops that these activities should pro-
ceed without firm evidence. Indeed, because of the lack of evidence for
effectiveness and the large investment that would be required to implement a
blanket policy of close monitoring during high-risk periods for all patients, an
argument could be made that treatment resources might be better used for
mental health interventions with stronger evidence for effectiveness. Future
research using large datasets with more detailed information on potential
confounders and the development of new methodologies to address treatment
selection biases in observational data are clearly needed.
Study Limitations
Diagnoses, demographics, and cause of death may not be completely accurate
in administrative databases. However, VHA administrative data quality is
generally considered good, with high levels of concordance between VHA
administrative data and medical record data (Kashner 1998; Cowper et al.
1999). The NDI is also considered the ‘‘gold standard’’ of U.S. mortality da-
tabases (Cowper et al. 2002). Findings for VHA patients also may not gen-
eralize to non-VHA patient populations, and findings within the VHA may
change as greater numbers of younger veterans enter the health care system
following their return from Iraq or Afghanistan.
In summary, although expert and governmental recommendations have
urged closer monitoring for depressed patients during high-risk periods to
prevent suicide, strong evidence for this recommendation may be difficult to
generate. When using observational datasets to address this issue, IV analyses
appear less biased than case–control approaches; however, even with a very
large database, the application of the IV method appears limited due to low
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rate of suicide and the resulting increased variability of its estimate, making it
difficult to arrive at definite answers regarding this relationship.
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